Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to
announce that its wholly owned subsidiary Biocannabix Health
Corporation Inc., has completed necessary compliance process and
obligations for the acquisition for exclusive licensing with
cannabis company Cannakids®.
The Company’s Pediatric Cannabinoid
Strategy Biocannabix Health Corporation, a
wholly-owned subsidiary of Relevium is focusing on delivering all
the potential health benefits of cannabinoid formulations in full
compliance of the legal and regulatory framework to Pediatric
patients in Canada. The company will focus initially on
nutraceutical formulations aimed at behavioral and developmental
conditions including ADHD and Hyperactivity amongst others. The
Company’s initial focus will be on education, compliance, branding
and developing a fully auditable supply chain of Cannakids products
nationwide.
Aurelio Useche, CEO stated: “According to
Tecnavio2018, the global pediatric market for medicines will reach
121 billion by 2021 and we intend to lead the way in Endo-Medicinal
Nutraceuticals.” Mr. Useche stated further: “We are delighted to
have completed this lengthy process and very keen to start working
towards building the pathway to the full commercialization of
Pediatric Endo-Medicinal Nutraceuticals in partnership with
Cannakids®.”
Biocannabix and the Exclusive Cannakids®
LicenseOn December 13, 2019 the Company announced it had
renegotiated and restructured the original investment transaction
in favour of an exclusive license of intellectual property,
including formulations, SOPs and patient data for pediatric
applications for the Canadian market. Under the exclusive licence
agreement, Relevium has made an initial investment of CAD$1.3
Million through the issue of 11,911,111 shares and CAD$200,000 in
cash.
The licensing agreement between Biocannabix and
Cannakids® grants the exclusive Canadian rights to the CannaKids IP
including formulations, SOPs, dosing, titration and patient data
with a Royalty on sales of 13%.
Tracy Ryan, CEO of Cannakids®, stated: “The
Cannakids team is ecstatic to now be extending our reach into
Canada. It has always been our goal to help patients on a global
scale, and we are proud to have Relevium as our Canadian partner to
help us take that next step in making our dreams a reality. We look
forward to helping Canadians find holistic relief from their
ailments, all while working towards expanding our research to
patients both, young and old.”
About Relevium Technologies
Relevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operations of brands and businesses in
the Health and Wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including such as
Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec,
is a biopharma nutraceutical company focused on delivering
pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
About Cannakids®CannaKids.org
is a privately held company that has provided CO2 extracted, lab
tested cannabis oil products to thousands of patients over the past
4 years. Using nurse guided assistance, the brand has been
synonymous with some of the most recognized patient success stories
in the world. Catering to Patients of All Ages, Cannakids employs
medical experts with dosing expertise that span across hundreds of
ailments. The Company has indication specific formulations backed
by anecdotal, in-house patient data, recent research, and medical
findings from their partners at the Technion Institute in
Israel.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Cautionary Note Regarding Forward-Looking
StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, including the timing and completion of the proposed
acquisitions, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including the assumptions that the Company will be able to apply
for and ultimately obtain an ACMPR licence, the proposed business
of Biocannabix will develop as anticipated, that the Company will
raise sufficient funds to develop the Biocannabix business, and
that the Company will obtain all requisite regulatory approvals.
These forward-looking statements are subject to known and unknown
risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of the
Company to be materially different from those expressed or implied
by such forward-looking statements or forward-looking information.
Important factors that may cause actual results to vary, include,
without limitation, the risk that the proposed business
developments may not occur as planned; the timing and receipt of
requisite approvals and failure to raise sufficient funds.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek safe
harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.comWebsite:
www.releviumtechnologies.com Like us on FacebookFollow us on
TwitterFollow us on LinkedIn
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024